Corvus Pharmaceuticals
Clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer.
Launch date
Employees
Market cap
€290m
Enterprise valuation
€248m (Public information from Sep 2024)
Share price
$5.61 CRVS
Burlingame California (HQ)
Authorizing premium user...